ScholarIQanswers from OpenAlex & ORCID
William T. Barry
ResearcherPublications, citations & collaboration network
William T. Barry is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does William T. Barry have?
ScholarIQindexed works
William T. Barry has 363 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does William T. Barry have?
ScholarIQcitation count
William T. Barry has 16,326 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of William T. Barry?
ScholarIQh-index
William T. Barry has an h-index of 63 in OpenAlex.
What is the i10-index of William T. Barry?
ScholarIQi10-index
William T. Barry has an i10-index of 167 in OpenAlex.
What is the OpenAlex record for William T. Barry?
ScholarIQopenalex
The OpenAlex for William T. Barry is on the source record.
What are the most-cited papers on William T. Barry?
ScholarIQmost cited works
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Sara M. Tolaney, William T. Barry, Chau T. Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Beth Overmoyer, Ann H. Partridge, Hao Guo, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Eric P. Winer
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shaokun Shu, Charles Y. Lin, Housheng Hansen He, Robert M. Witwicki, Doris P. Tabassum, Justin M. Roberts, Michalina Janiszewska, Sung Jin Huh, Yi Liang, Jeremy Ryan, Ernest Doherty, Hisham Mohammed, Hao Guo, Daniel G. Stover, Muhammad B. Ekram, Guillermo Peluffo, Jonathan D. Brown, Clive S. D’Santos, Ian E. Krop, Deborah Dillon, Michael R. McKeown, Christopher J. Ott, Jun Qi, Min Ni, Prakash K. Rao, Melissa Duarte, Shwu-Yuan Wu, Cheng-Ming Chiang, Lars Anders, Richard A. Young, Eric P. Winer, Antony Letai, William T. Barry, Jason S. Carroll, Henry W. Long, Myles Brown, X. Shirley Liu, Clifford A. Meyer, James E. Bradner, Kornélia Polyák
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A. Carey, Donald A. Berry, Constance Cirrincione, William T. Barry, Brandelyn N. Pitcher, Lyndsay N. Harris, David W. Ollila, Ian E. Krop, N. Lynn Henry, Douglas Weckstein, Carey K. Anders, Baljit Singh, Katherine A. Hoadley, Michael D. Iglesia, Maggie C.U. Cheang, Charles M. Perou, Eric P. Winer, Clifford A. Hudis
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A. Konstantinopoulos, William T. Barry, Michael J. Birrer, Shannon N. Westin, Karen A. Cadoo, Geoffrey I. Shapiro, Erica L. Mayer, Roisin E. O’Cearbhaill, Robert L. Coleman, Bose Kochupurakkal, Christin Whalen, Jennifer Curtis, Sarah Farooq, Weixiu Luo, Julia Eismann, Mary K. Buss, Carol Aghajanian, Gordon B. Mills, Sangeetha Palakurthi, Paul T. Kirschmeier, Joyce F. Liu, Lewis C. Cantley, Scott H. Kaufmann, Elizabeth M. Swisher, Alan D. D’Andrea, Eric P. Winer, Gerburg M. Wulf, Ursula A. Matulonis
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
Yemil Atisha‐Fregoso, Susan Malkiel, Kristina M. Harris, M. Byron, Linna Ding, Sai Kanaparthi, William T. Barry, Wendy Gao, Kristin Ryker, Patti Tosta, Anca Askanase, Susan A. Boackle, W. Winn Chatham, Diane L. Kamen, David R. Karp, Kyriakos A. Kirou, S. Sam Lim, Bradley Marder, Maureen McMahon, Samir V. Parikh, William F. Pendergraft, Amber S. Podoll, Amit Saxena, David Wofsy, Betty Diamond, Dawn E. Smilek, Cynthia Aranow, Maria Dall’Era